ORGAN TRANSPLANT REJECTION AND ASSOCIATED CONDITIONS

ORGAN TRANSPLANT REJECTION AND ASSOCIATED CONDITIONS

The application discloses markers associated with organ transplant rejection and associated conditions, and in particular provides materials and methods for the diagnosis, prognosis or treatment of chronic rejection of transplanted organ such as heart and kidney. Examples of the markers include ribo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ROSE, MARLENE, LYDIA, LINKE, ADAM, DUNN, MICHAEL, JOHN
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ROSE, MARLENE, LYDIA
LINKE, ADAM
DUNN, MICHAEL, JOHN
description The application discloses markers associated with organ transplant rejection and associated conditions, and in particular provides materials and methods for the diagnosis, prognosis or treatment of chronic rejection of transplanted organ such as heart and kidney. Examples of the markers include ribosomal protein L7, beta -transducin, 1-TRAF (also known as TANK) or lysyl-tRNA synthetase, or antibodies against these antigens. La présente invention concerne des marqueurs associés au rejet d'un organe transplanté et les états pathologiques associés, et concerne en particulier des matériaux et des procédés permettant de diagnostiquer, de prévoir ou de traiter le rejet chronique d'un organe transplanté tel qu'un coeur ou un rein. Les marqueurs comprennent par exemple la protéine ribosomale L7, la beta -transducine, la 1-TRAF (appelée également TANK) ou lysyl-ARNt synthase, ou des anticorps contre ces antigènes.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO0140302A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO0140302A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO0140302A33</originalsourceid><addsrcrecordid>eNrjZDDxD3J39FMICXL0Cw7wcfQLUQhy9XJ1DvH091Nw9HNRcAwO9nf2dAxxdVFw9vdz8QRJBPMwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUkvhwfwNDEwNjAyNHY2MilAAAj1QnKw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ORGAN TRANSPLANT REJECTION AND ASSOCIATED CONDITIONS</title><source>esp@cenet</source><creator>ROSE, MARLENE, LYDIA ; LINKE, ADAM ; DUNN, MICHAEL, JOHN</creator><creatorcontrib>ROSE, MARLENE, LYDIA ; LINKE, ADAM ; DUNN, MICHAEL, JOHN</creatorcontrib><description>The application discloses markers associated with organ transplant rejection and associated conditions, and in particular provides materials and methods for the diagnosis, prognosis or treatment of chronic rejection of transplanted organ such as heart and kidney. Examples of the markers include ribosomal protein L7, beta -transducin, 1-TRAF (also known as TANK) or lysyl-tRNA synthetase, or antibodies against these antigens. La présente invention concerne des marqueurs associés au rejet d'un organe transplanté et les états pathologiques associés, et concerne en particulier des matériaux et des procédés permettant de diagnostiquer, de prévoir ou de traiter le rejet chronique d'un organe transplanté tel qu'un coeur ou un rein. Les marqueurs comprennent par exemple la protéine ribosomale L7, la beta -transducine, la 1-TRAF (appelée également TANK) ou lysyl-ARNt synthase, ou des anticorps contre ces antigènes.</description><edition>7</edition><language>eng ; fre</language><subject>CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES</subject><creationdate>2002</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20020321&amp;DB=EPODOC&amp;CC=WO&amp;NR=0140302A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20020321&amp;DB=EPODOC&amp;CC=WO&amp;NR=0140302A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ROSE, MARLENE, LYDIA</creatorcontrib><creatorcontrib>LINKE, ADAM</creatorcontrib><creatorcontrib>DUNN, MICHAEL, JOHN</creatorcontrib><title>ORGAN TRANSPLANT REJECTION AND ASSOCIATED CONDITIONS</title><description>The application discloses markers associated with organ transplant rejection and associated conditions, and in particular provides materials and methods for the diagnosis, prognosis or treatment of chronic rejection of transplanted organ such as heart and kidney. Examples of the markers include ribosomal protein L7, beta -transducin, 1-TRAF (also known as TANK) or lysyl-tRNA synthetase, or antibodies against these antigens. La présente invention concerne des marqueurs associés au rejet d'un organe transplanté et les états pathologiques associés, et concerne en particulier des matériaux et des procédés permettant de diagnostiquer, de prévoir ou de traiter le rejet chronique d'un organe transplanté tel qu'un coeur ou un rein. Les marqueurs comprennent par exemple la protéine ribosomale L7, la beta -transducine, la 1-TRAF (appelée également TANK) ou lysyl-ARNt synthase, ou des anticorps contre ces antigènes.</description><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2002</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDDxD3J39FMICXL0Cw7wcfQLUQhy9XJ1DvH091Nw9HNRcAwO9nf2dAxxdVFw9vdz8QRJBPMwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUkvhwfwNDEwNjAyNHY2MilAAAj1QnKw</recordid><startdate>20020321</startdate><enddate>20020321</enddate><creator>ROSE, MARLENE, LYDIA</creator><creator>LINKE, ADAM</creator><creator>DUNN, MICHAEL, JOHN</creator><scope>EVB</scope></search><sort><creationdate>20020321</creationdate><title>ORGAN TRANSPLANT REJECTION AND ASSOCIATED CONDITIONS</title><author>ROSE, MARLENE, LYDIA ; LINKE, ADAM ; DUNN, MICHAEL, JOHN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO0140302A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2002</creationdate><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><toplevel>online_resources</toplevel><creatorcontrib>ROSE, MARLENE, LYDIA</creatorcontrib><creatorcontrib>LINKE, ADAM</creatorcontrib><creatorcontrib>DUNN, MICHAEL, JOHN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ROSE, MARLENE, LYDIA</au><au>LINKE, ADAM</au><au>DUNN, MICHAEL, JOHN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ORGAN TRANSPLANT REJECTION AND ASSOCIATED CONDITIONS</title><date>2002-03-21</date><risdate>2002</risdate><abstract>The application discloses markers associated with organ transplant rejection and associated conditions, and in particular provides materials and methods for the diagnosis, prognosis or treatment of chronic rejection of transplanted organ such as heart and kidney. Examples of the markers include ribosomal protein L7, beta -transducin, 1-TRAF (also known as TANK) or lysyl-tRNA synthetase, or antibodies against these antigens. La présente invention concerne des marqueurs associés au rejet d'un organe transplanté et les états pathologiques associés, et concerne en particulier des matériaux et des procédés permettant de diagnostiquer, de prévoir ou de traiter le rejet chronique d'un organe transplanté tel qu'un coeur ou un rein. Les marqueurs comprennent par exemple la protéine ribosomale L7, la beta -transducine, la 1-TRAF (appelée également TANK) ou lysyl-ARNt synthase, ou des anticorps contre ces antigènes.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO0140302A3
source esp@cenet
subjects CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
title ORGAN TRANSPLANT REJECTION AND ASSOCIATED CONDITIONS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A10%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ROSE,%20MARLENE,%20LYDIA&rft.date=2002-03-21&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO0140302A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true